Clobazam: 4 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 13.1 years separate the first record, 24 May 2013 at AWMSG (Wales), from the most recent, 17 Jun 2026 at CIPM (Spain).
CIPM (Spain) changed its position: not recommended on 8 Jul 2021, recommended by 17 Jun 2026, after a resubmission.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 6 of 11 records date from 2023 or later.
Against its own class, clobazam is an outlier: 30% of its decisive outcomes were positive, where molecules sharing ATC class N05B average 66%.
AWMSG (Wales) was first to assess clobazam, on 24 May 2013; TLV (Sweden) did not open a file until 18 Apr 2023 — an unusually long tail of 9.9 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 4 agencies here assessed clobazam more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed clobazam.
The full ledger for clobazam reads 7 not recommended, 3 recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 25 Feb 2026 | Indicación terapéutica autorizada: Clobazam está indicado en adultos o niños mayores de 2 años para el tratamiento coady… | not financed by the SNS (financed 2026-06) | source |
| HAS (France) | 10 Dec 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| CIPM (Spain) | 24 Sep 2025 | Indicación terapéutica autorizada: Clobazam está indicado en adultos o niños mayores de 2 años para el tratamiento coady… | not financed by the SNS (financed 2026-06) | source |
| TLV (Sweden) | 18 Apr 2023 | Clobazam 1A Farma ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| AWMSG (Wales) | 24 May 2013 | Short-term relief (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable dis… | outside AWMSG criteria | source |
6 further decisions for clobazam, across 3 agencies, are not shown here. They include the most recent record on file, 17 Jun 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- diazepam — same ATC class N05B — Psycholeptics
- vutrisiran — also decided by CIPM in 2026Q2
- omalizumab — also decided by CIPM in 2026Q2
- azithromycin — also decided by CIPM in 2026Q2
- finerenone — also decided by CIPM in 2026Q2
- ibrutinib — also decided by CIPM in 2026Q2
Coverage: 11 decisions for clobazam from 4 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class N05B — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.